PIK3CD and neoplasm: Preclinical and clinical studies have highlighted the potential of targeting the PI3K pathway as a therapeutic intervention for gastrointestinal tumors mainly based on the influence on tumor resistance to antineoplastic drugs (Ng et al., 2000; O’gorman and Cotter, 2001; Mueller et al., 2012; Du J. et al., 2022).